Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Conventional fractionation, low-dose hypofractionated radiotherapy, or high-dose hypofractionated radiotherapy may be employed.

5 mg/kg, intravenously infused on Day 1 of each cycle, administered every 3 weeks (with each cycle defined as 21 days).

35 mg/m², orally twice daily on Days 1 to 5 and Days 8 to 12 of each cycle, with each cycle spanning 28 days (4 weeks).

7.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.